Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/60048
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrice, T.en
dc.contributor.authorTebbutt, N.en
dc.contributor.authorKarapetis, C.en
dc.contributor.authorSegelov, E.en
dc.contributor.authorPavlakis, N.en
dc.contributor.authorCunningham, D.en
dc.contributor.authorSobrero, A.en
dc.contributor.authorHaller, D.en
dc.contributor.authorShapiro, J.en
dc.date.issued2010en
dc.identifier.citationClinical Colorectal Cancer, 2010; 9(1):8-14en
dc.identifier.issn1533-0028en
dc.identifier.issn1938-0674en
dc.identifier.urihttp://hdl.handle.net/2440/60048-
dc.description.abstractThe medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in the past 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of the targeted monoclonal antibodies bevacizumab, cetuximab, and panitumumab in the treatment of patients with mCRC is now well-established, but the optimal timing of their use requires careful consideration in order to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and epidermal growth factor receptor-targeted biologic agents (cetuximab and panitumumab) in the treatment of patients with mCRC. This article reviews the evidence in support of modern treatments for mCRC and the decision making behind the treatment choices as well as their benefits and toxicities. An evidence-based algorithm is proposed that incorporates the use of these biologic agents early in the treatment of patients with initially nonresectable mCRC based on clearly defined tumor-related factors dependent on the immediate treatment goal. Real-world application of this algorithm is dependent on an individual countries' approval of access to new biologic agents.en
dc.description.statementofresponsibilityTimothy J. Price, Niall C. Tebbutt, Christos S. Karapetis, Eva Segelov, Nick Pavlakis, David Cunningham, Alberto F. Sobrero, Daniel G. Halle and Jeremy D. Shapiroen
dc.language.isoenen
dc.publisherCIG Media Group, L.P.en
dc.rightsCopyright status unknownen
dc.subject5-Fluorouracil; Bevacizumab; Capecitabine; Cetuximab; KRAS; Vascular endothelial growth factoren
dc.titleCurrent opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: Report from the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008en
dc.typeJournal articleen
dc.identifier.rmid0020100182en
dc.identifier.doi10.3816/CCC.2010.n.001en
dc.identifier.pubid33741-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidPrice, T. [0000-0002-3922-2693]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.